Distribution of Anti Factor Xa Activity in Patients on Edoxaban Therapy for Non Valvular Atrial Fibrillation.
BACKGROUND The distribution of anti factor Xa activity (AXA) values in non valvular atrial fibrillation (NVAF) patients on edoxaban therapy has not been fully elucidated. METHODSANDRESULTS The steady state trough and peak AXA values were measured in 66 NVAF patients. The trough AXA value did not differ significantly between the 60 mg and the 30 mg OD groups (0.17+ 0.13 IU/ml vs. 0.12+ 0.11 IU/ml, respectively; P=0.17) Similarly, the peak AXA value did not differ significantly between the 2 groups (1.45+ 0.81 IU/ml vs. 1.25+ 0.48 IU/ml, respectively; P=0.26) CONCLUSIONS Recommended dosing should be followed for sufficient efficacy of edoxaban. (Circ J 2016; 80: 745 747)
Circulation journal official journal of the Japanese Circulation Society